evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 3 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 1 · 16.7%High 1 · 16.7%

Bortezomib vs no bortezomib

Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma

Bortezomib showed no clear difference in adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma

Bortezomib may leads to higher adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review